We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF
PJP

93 hedge funds and large institutions have $59M invested in Invesco Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

14% more capital invested

Capital invested by funds: $51.8M → $59M (+$7.22M)

1% more funds holding

Funds holding: 92 → 93 (+1)

0.05% less ownership

Funds ownership: 22.28% → 22.23% (-0.05%)

17% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 23

Holders
93
Holders Change
+1
Holders Change %
+1.09%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
19
Reduced
23
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$730K
2
Goldman Sachs
Goldman Sachs
New York
+$635K
3
LPL Financial
LPL Financial
California
+$510K
4
Citadel Advisors
Citadel Advisors
Florida
+$477K
5
WI
WBI Investments
New Jersey
+$472K

Top Sellers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$799K
2
Wells Fargo
Wells Fargo
California
-$651K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$545K
4
TRCT
Tower Research Capital (TRC)
New York
-$408K
5
SWGC
Summit Wealth Group (Colorado)
Colorado
-$366K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
1
Peak Asset Management
Colorado
$12.7M +$85.3K +975 +0.7%
LPL Financial
2
LPL Financial
California
$5.2M +$510K +5,828 +12%
UBS Group
3
UBS Group
Switzerland
$3.52M -$190K -2,166 -5%
Morgan Stanley
4
Morgan Stanley
New York
$3.45M -$175K -1,998 -5%
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$2.25M -$90.2K -1,030 -4%
Goldman Sachs
6
Goldman Sachs
New York
$2.15M +$635K +7,251 +45%
Bank of America
7
Bank of America
North Carolina
$2.13M -$6.3K -72 -0.3%
JGCM
8
Joseph Group Capital Management
Ohio
$2.05M +$77.8K +889 +4%
MWM
9
MGB Wealth Management
Texas
$1.95M -$6.39K -73 -0.3%
Wells Fargo
10
Wells Fargo
California
$1.78M -$651K -7,433 -28%
DBIA
11
Dumont & Blake Investment Advisors
New Jersey
$1.76M -$8.23K -94 -0.5%
Envestnet Asset Management
12
Envestnet Asset Management
Illinois
$1.69M -$110K -1,259 -6%
TC
13
Trilogy Capital
California
$1.49M -$49.4K -564 -3%
IFWM
14
Institute for Wealth Management
Colorado
$1.15M -$25.1K -287 -2%
Ameriprise
15
Ameriprise
Minnesota
$1.11M +$730K +8,344 +214%
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$935K -$160K -1,832 -15%
Raymond James Financial
17
Raymond James Financial
Florida
$934K +$7K +80 +0.8%
Cambridge Investment Research Advisors
18
Cambridge Investment Research Advisors
Iowa
$817K -$44.8K -512 -5%
Wealth Enhancement Advisory Services
19
Wealth Enhancement Advisory Services
Minnesota
$700K -$8.75K -100 -1%
Cetera Investment Advisers
20
Cetera Investment Advisers
Illinois
$552K +$438 +5 +0.1%
FHA
21
Flagship Harbor Advisors
Massachusetts
$550K – – –
Focus Partners Wealth
22
Focus Partners Wealth
Massachusetts
$546K – – –
Citadel Advisors
23
Citadel Advisors
Florida
$504K +$477K +5,448 New
IDA
24
Intelligence Driven Advisers
California
$499K – – –
WI
25
WBI Investments
New Jersey
$499K +$472K +5,395 New
1
2 3 4

PJP Hedge Fund Activity: Q3 2025 in Review

93 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q3 2025, worth a combined $59M — up 14% from $51.8M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new PJP positions and 7 closed out — a net gain of 1 holder — while 19 added to existing stakes and 23 trimmed.

The largest buyer was Ameriprise, adding an estimated $730K. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $799K sold.

  • 93 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q3 2025, up from 92 in Q2 2025.
  • Funds reported $59M of Invesco Pharmaceuticals ETF stock for Q3 2025, up 14% quarter-over-quarter.
  • 8 funds opened new Invesco Pharmaceuticals ETF positions in Q3 2025 and 7 closed out, a net change of +1 holder.
  • The largest Invesco Pharmaceuticals ETF buyer in Q3 2025 was Ameriprise, an estimated $730K added.
  • The largest Invesco Pharmaceuticals ETF seller in Q3 2025 was BNP Paribas Financial Markets, an estimated $799K sold.

Based on aggregated 13F filings for Q3 2025.